The list of stocks hedge funds are buying is always lengthy but according to Morgan Stanley, hedge funds have been allocating capital to a select group of beaten down stocks on expectations that they will likely rebound in the coming months. Hedge funds are taking advantage of the 3% and 4% decline in European and
admin
With Alphabet (NASDAQ:GOOG, NASDAQ:GOOGL) stock poised to benefit tremendously from the rapidly rebounding digital advertising market and the proliferation of artificial intelligence (AI), Alphabet’s shares are definitely worth buying at this point. What’s more, the company is growing rapidly, while the valuation of GOOG stock remains attractive. The U.S. Digital Ad Market’s Comeback and the
Suffice it to say, Clorox (NYSE:CLX) is roundly unloved on Wall Street right now. The pessimism may continue for a little while longer, so don’t be too early if you’re planning to buy CLX stock. It shouldn’t be too much longer before a big window of opportunity opens up, however. Clorox is America’s famous seller
Since going public in June 2021, SoFi Technologies (NASDAQ:SOFI) hasn’t met investor expectations. Despite a 59% drop from its IPO price, it rebounded in 2023, surging 98%. Before buying, it’s crucial to consider the pros and cons of this fintech stock. Moreover, SOFI has experienced a rollercoaster ride. Despite facing challenges due to the extended
Immediately following the initial shock of the COVID-19 pandemic, the narrative of low-volatility stocks admittedly didn’t make much sense. With the benefit of hindsight, we can see that the additional influx of cash that retail investors had poured into higher-risk ventures. As a result, the traditional safe stocks fell by the wayside, replaced with a
As investors and traders alike have settled into the “higher for longer” mindset for interest rates, U.S. equities have experienced a lot of selling pressure in recent weeks. The S&P 500 is down 2% in the last 3 months, while the Nasdaq has fallen 1.44%. However, bearish times can still present good moments to invest
While enterprises with diminutive market capitalizations tend to be high-risk, high-reward ventures, you can shift the odds in your favor with small-cap stocks with buy ratings. Thanks to the nod from Wall Street experts, you can feel a little bit more comfortable with the speculative step that you’re taking. Now, to be 100% clear, small-cap
While innovations such as artificial intelligence have taken off, the “analog” segment of the market – the anti-AI stocks if you will – have fell by the wayside. Frankly, that’s an understandable dynamic given the paradigm-shifting potential of advanced technologies. Nevertheless, you don’t want to ignore the old-school fundamentals. Yes, seemingly everything in society focuses
The early investors in Tesla have already minted money. However, the electric vehicle sector is likely to create more millionaires in the coming years. Given the fact that EVs are still at an early stage of adoption globally, headroom for growth is immense for some of the best EV companies. It’s time to focus on
During the Covid-19 pandemic, there was a surge in online gaming stocks even as casinos took a hit. In a post-pandemic era, there seems to be a fine balance between online and offline gaming. Virtual reality gaming also promises to be a game-changer for the industry. By 2026, the market for VR and AR gaming
Investors can choose from thousands of stocks, and while that may sound like a good thing, more choices aren’t always better. It’s easy to get overwhelmed by the number of available stocks and miss out on compelling opportunities. Luckily, stock analysts simplify deciphering good stocks from less promising ones. These experts offer price targets and
With the stock market slump since the start of August, investors have new opportunities to buy several leading blue-chip stocks at bargain prices. Many well-known companies and household names had share prices fall 10% or more since mid-summer, when all three major U.S. indices declined on renewed worries of sticky inflation, elevated interest rates, and
These seven stocks are in trouble. While the broader market struggles with ongoing interest rate hikes, constrained cash and more, these seven stocks suffer more than most. But all hope isn’t lost — if the companies can mount buyouts. Oftentimes, larger firms hunt for smaller firms with a semi-viable product or existing operational model for
The future of solar is bright and governments across the world are trying their best to achieve their goal to transition towards a carbon-free electric grid. This is spelling big things for solar stocks. While it is easier said than done, we have seen tremendous progress this year and I believe this momentum is set
The debt woes facing corporate America are real, as indicated by an increase in debt defaults. In July, Business Insider reported that 55 U.S. companies had defaulted within the first six months of the year, 53% higher than a year earlier. “A tougher credit environment combined with a full-blown recession could result in nearly a
In the landscape of AI, certain companies stand out as titans of rapid and robust growth. As the world ventures into 2024, three AI stocks promise exciting opportunities and transformative forces that will shape industries and redefine possibilities. Having said that, there are some game-changing AI stocks that you should consider adding to your portfolio.
In 2023, stocks have generally fared better than the previous year. Yet, some high-growth stocks have slowed down amid uncertainties like a potential recession and higher interest rates. Despite a strong first half of the year, major indexes have recently retreated. This pullback has created an opportunity to invest in industry-leading companies at reduced prices.
Pity the average cannabis stock investor. Since 2021, shares of the largest cannabis fund, the AdvisorShares Pure US Cannabis ETF (NYSEARCA:MSOS) have lost over 80% of their value. Many companies have fared even worse. MedMen (OTCMKTS:MMNFF) — once considered the “Apple store of weed” — has seen its valuation plummet from $1.7 billion to $40
A box of Ozempic, a semaglutide injection drug used for treating Type 2 diabetes made by Novo Nordisk. George Frey | Reuters Check out the companies making big moves midday. Novo Nordisk — The Danish drugmaker stock added 5.5% after saying late Tuesday it was halting Ozempic’s kidney disease treatment trial after a committee said
Defensive stocks are well known to value investors. These stocks are recognized for being fairly priced and offering investors strong fundamentals. In addition to those shared attributes, defensive stocks are those companies that offer products and services that consumers and businesses need regardless of what’s happening in the economy. Sticky inflation, interest rates that will